Shield Therapeutics upbeat as Accrufer trial initiated in Japan
(Alliance News) - Shield Therapeutics PLC on Friday reported the commencement of a phase two Accrufer trial in Japan for the treatment of pulmonary arterial hypertension. Read More
| Price | 11.75p on 17-12-2025 at 19:25:08 |
|---|---|
| Change | 0.55p 4.91% |
| Buy | 12.00p |
| Sell | 11.50p |
| Last Trade: | Sell 49,676.00 at 11.50p |
| Day's Volume: | 2,635,827 |
| Last Close: | 11.75p |
| Open: | 11.20p |
| ISIN: | GB00BYV81293 |
| Day's Range | 11.20p - 12.00p |
| 52wk Range: | 2.20p - 12.35p |
| Market Capitalisation: | £124.76m |
| VWAP: | 11.75672p |
| Shares in Issue: | 1.06b |
Sector: Medicine and Biotech
Listed In: FTSE AIM All-Share,
Shield Thera (STX) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 49,676 | 11.50p | Ordinary |
15:59:58 - 17-Dec-25 |
| Sell* | 6,522 | 11.50p | Ordinary |
15:56:27 - 17-Dec-25 |
| Sell* | 19,500 | 11.50p | Ordinary |
15:54:20 - 17-Dec-25 |
| Buy* | 84,141 | 11.88p | Ordinary |
15:44:21 - 17-Dec-25 |
| Sell* | 5,000 | 11.50p | Ordinary |
15:40:22 - 17-Dec-25 |
| Sell* | 19,000 | 11.50p | Ordinary |
15:37:59 - 17-Dec-25 |
| Sell* | 25,000 | 11.50p | Ordinary |
15:19:32 - 17-Dec-25 |
| Buy* | 10,000 | 11.88p | Ordinary |
15:15:04 - 17-Dec-25 |
| Sell* | 4,000 | 11.50p | Ordinary |
15:14:35 - 17-Dec-25 |
| Buy* | 42,105 | 11.875p | Ordinary |
15:09:34 - 17-Dec-25 |
Shield Thera (STX) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 11th Dec 2025 7:00 am | RNS-R | Shield Wins Gold at Titan Branding Awards |
| 3rd Dec 2025 7:04 am | RNS | Amends Senior Secured Debt Financing |
| 14th Nov 2025 7:03 am | RNS | Initiation of a Phase II Clinical Trial in Japan |
| 11th Nov 2025 7:00 am | RNS | ACCRUFeR Pediatric PK Results to be Presented |
| 7th Nov 2025 7:03 am | RNS | ACCRUFeR receives Authorisation by Korean Ministry |
| 23rd Oct 2025 7:00 am | RNS | Q3 2025 Trading Update |
| 14th Oct 2025 3:01 pm | RNS | Grant of Share Options to Chief Executive Officer |
| 1st Oct 2025 8:00 am | RNS | Total Voting Rights |
| 1st Oct 2025 7:02 am | RNS | Positive efficacy and tolerance in pediatric trial |
| 15th Sep 2025 7:00 am | RNS | £1.5 million placing supporting growth of ACCRUFeR |